Company Overview and News
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Storage assets are probably the most boring assets in the midstream space (please don't stop reading!). Something about storing a hydrocarbon is generally less exciting than processing hydrocarbons or transporting them. While storage assets are important, they are not often in the spotlight. However, with the shift in the oil curve from contango to backwardation, now seems like a good time to discuss storage and oil curve backwardation and the implications for MLPs with oil storage capacity.
So far in this series, we have discussed the performance of the broader MLP sector, the top MLP gainers, and the top MLP losers in the week ending April 13, 2018. In this part, we’ll discuss the MLP rating updates last week.
Magellan Midstream Partners (MMP) stock has fallen nearly 11% so far in 2018. It’s underperformed its peers Enterprise Products Partners (EPD) and Plains All American Pipeline (PAA) during this period.
Kinder Morgan (KMI) is expected to report net income of $489 million for 1Q18, which is 32% higher than its 1Q17 net income. Its expected net income is 4% higher than 4Q17. Kinder Morgan beat its net income estimates in only three of the last ten quarters. Analyst-adjusted net income for KMI for 4Q17 was $469 million, beating estimates by 14%.
Investors occasionally ask us what distribution coverage looks like for MLPs. While it may seem straightforward, it is somewhat of a loaded question. Distribution coverage (or coverage ratio) compares distributable cash flow (DCF) generated in a period to the total cash distributions paid for that period. Investors look at distribution coverage to better understand an MLP's ability to pay distributions from the cash generated by its operations.
Magellan Midstream Partners (MMP) continues to trade significantly below its 50-day and 200-day moving average, which might indicate bearish sentiment in the stock. Magellan Midstream Partners was trading 5.8% below its 50-day simple moving average and 11.1% below its 200-day simple moving average as of April 6, 2018.
The Alerian MLP ETF (AMLP), which is comprised of 25 energy MLPs, continued to see strong inflows despite recent volatility in the midstream energy sector. Last week, AMLP saw the highest weekly inflow in 2018. AMLP saw an inflow of $161.8 million funds. AMLP has seen a net inflow of $293.4 million in the past three weeks. AMLP’s strong inflows despite recent volatility could be attributed to MLPs’ attractive valuations.
SunCoke Energy Partners (SXCP), an MLP involved in the production of coke used in steelmaking, saw new analyst coverage last week. Seaport Global Securities initiated coverage on SunCoke Energy Partners with a “buy” rating and assigned a target price of $21. Previously, SunCoke Energy Partners saw a rating update in November 2016. Now, 50.0% of the analysts’ surveyed by Reuters rate SunCoke Energy Partners as a “buy” and 50% rate it as a “hold.
Kinder Morgan (KMI) is currently trading at a forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple of ~9.6x. That’s lower than its five-year average multiple of ~13.5x. Its current multiple is among the lowest in the last five years.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET